This website uses cookies to enhance the user experience.
G

GENOTEC HOLDING AS926 665 057

Research
Limited company
Operagata 69A 0194 OSLO, Norge

GENOTEC HOLDING AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
3 years
since Feb 24, 2021
Type
Limited company
VAT registered
No
Number of employees
0

Ownership

Number of shares and share classes
500
1 share class
Total number of shareholders
3
persons
Belongs to group of

Financials

Annual total result 2023
-1,598,573
NOK
Total equity 2023
-1,160,044
NOK
Last update: Aug 29, 2024

Management

Board

NameRoleShares
Contact Person, Chairman
60 %
directly
Board Member
20 %
directly
Board Member
20 %
directly

Others

NameRoleShares
B
BDO AS
Auditor-
H
HADELAND REGNSKAP AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Contact Person, Chairman
60 %
directly
Board Member
20 %
directly
Board Member
20 %
directly
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classNumber of sharesShare
Ordinary shares
300
60 %
Ordinary shares
100
20 %
Ordinary shares
100
20 %

Shares owned by the GENOTEC HOLDING AS

NameShare classNumber of sharesShare
G
GENOFUEL AS
Ordinary shares
500
100 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -26,645
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
0
0
0
Annual Total Result
-1,598,573
-29,080
-26,822
Total assets
668,997
1,688,716
685,168
Total liabilities
1,829,041
1,250,188
217,559
Total equity
-1,160,044
438,528
467,609

P&L

Year202320222021
Total operating income
0
0
0
Total operating costs
26,645
29,080
26,822
Operating result
-26,645
-29,080
-26,822
Financial income/costs
-1,571,928
0
0
Profit before tax
-1,598,573
-29,080
-26,822
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-1,598,573
-29,080
-26,822

Balance overview

Year202320222021
Total fixed assets
667,225
1,670,925
500,000
Total current assets
1,772
17,791
185,168
Total assets
668,997
1,688,716
685,168
Short term debt
1,829,041
1,250,188
217,559
Long term debt
0
0
0
Total liabilities
1,829,041
1,250,188
217,559
Contributed capital
494,430
494,430
494,430
Retained earnings
-1,654,474
-55,902
-26,822
Total equity
-1,160,044
438,528
467,609
Total equity and liabilities
668,997
1,688,716
685,168

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology